Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytodyn Inc (CYDY)

Cytodyn Inc (CYDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 331,526
  • Shares Outstanding, K 1,278,543
  • Annual Sales, $ 0 K
  • Annual Income, $ 3,750 K
  • EBIT $ -36 M
  • EBITDA $ -35 M
  • 60-Month Beta 1.13
  • Price/Sales N/A
  • Price/Cash Flow 80.46
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on 10/10/25
  • Next Earnings Date 04/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2292 +13.13%
on 01/30/26
0.2800 -7.39%
on 02/19/26
+0.0005 (+0.19%)
since 01/20/26
3-Month
0.2292 +13.13%
on 01/30/26
0.3799 -31.75%
on 11/24/25
-0.0407 (-13.57%)
since 11/20/25
52-Week
0.1925 +34.70%
on 04/07/25
0.4945 -47.56%
on 02/24/25
+0.0103 (+4.14%)
since 02/20/25

Most Recent Stories

More News
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety Profile Observed in Heavily Pretreated...

CYDY : 0.2593 (-3.28%)
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...

CYDY : 0.2593 (-3.28%)
December 2025 Letter to Shareholders

VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for...

CYDY : 0.2593 (-3.28%)
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with...

CYDY : 0.2593 (-3.28%)
CytoDyn Announces Resolution of Class Action Lawsuit

VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...

CYDY : 0.2593 (-3.28%)
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Company to deliver a poster presentation on clinical data demonstrating sustained remission following immune checkpoint inhibitor therapy with or after leronlimab treatment in patients with metastatic...

CYDY : 0.2593 (-3.28%)
CytoDyn Secures $30 Million Commitment from Yorkville Advisors

VANCOUVER, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...

CYDY : 0.2593 (-3.28%)
Halper Sadeh LLC Encourages CytoDyn Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

CYDY : 0.2593 (-3.28%)
CytoDyn to Present at the LD Micro Main Event XIX Investor Conference

CFO Robert E. Hoffman to deliver company presentation on October 21, 2025 VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY)  ("CytoDyn" or the "Company"), a clinical-stage...

CYDY : 0.2593 (-3.28%)
September 2025 Letter to Shareholders

VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. (“CytoDyn” or the “Company”), I am pleased to...

CYDY : 0.2593 (-3.28%)

Business Summary

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has...

See More

Key Turning Points

3rd Resistance Point 0.2964
2nd Resistance Point 0.2877
1st Resistance Point 0.2735
Last Price 0.2593
1st Support Level 0.2506
2nd Support Level 0.2419
3rd Support Level 0.2277

See More

52-Week High 0.4945
Fibonacci 61.8% 0.3791
Fibonacci 50% 0.3435
Fibonacci 38.2% 0.3079
Last Price 0.2593
52-Week Low 0.1925

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar